Damora Therapeutics
DMRA on Nasdaq. Pharmaceutical preparations. Market value $1.2bn.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
Cash flow or capital spending isn't reported, so free cash flow is unknown.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
We could not compute this from the filings.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -229 cents a year. Above 10 is good.
Quality score: not known. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.
$19.55 a share, 295% above its 1-year low
Over the past year the price has ranged from $4.95 to $38.33.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares outstanding | |||||
| Shares outstanding | 0.03bn | 0.03bn | 0.00bn | 0.00bn | 0.06bn |
Health checks
- Free cash flow positive0 of 2 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)No
- Debt0.00× equity
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 141% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $31 million, compared with a loss of $3 million a year ago.
- 4521% more shares than a year ago. Each share owns a bit less of the company.
- It has $541 million more cash than debt, up from $10 million a year ago.
| Quarter to | Amount |
|---|---|
| September 2024 | -$4m |
| December 2024 | -$7m |
| March 2025 | -$3m |
| June 2025 | -$3m |
| September 2025 | -$3m |
| December 2025 | -$201m |
| March 2026 | -$28m |
| June 2026 | -$31m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 19 March 2026
- Next quarterly (estimated, 10-Q)
- 9 November 2026
Who owns it
None of the long-term investors we follow own it. 3 funds in all.
Largest holders overall
- Price T Rowe Associates$1mNew
- Harbour Investments$1,040New
- Rothschild Investment$884New
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- Fairmount Funds Management LLCInsider or founderat least 20.0%0.0 pts(filed with 4 related holders)Since 9 February 2026
What they said
Item 4 of the Statement is hereby amended and supplemented as follows: Conversion of Series C Preferred Stock Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock, dated November 7,…
Read the filing - FMR LLCPassive investorat least 15.0%(filed with 1 related holder)Since 28 November 2025
- Avoro Capital Advisors LLCPassive investorat least 6.3%(filed with 1 related holder)Since 31 March 2026
- Venrock Healthcare Capital Partners III, L.P.Passive investorat least 6.0%(filed with 6 related holders)Since 9 February 2026
- BlackRock, Inc.Passive investor5.1%Since 30 June 2026
- Point72 Asset Management, L.P.Passive investorat least 2.0%−4.3 pts(filed with 2 related holders)Since 31 March 2026
- Paragon Therapeutics, Inc.Passive investorSold down below 5%Since 9 February 2026
- Paramora Holding LLCPassive investorSold down below 5%Since 9 February 2026
- Ikarian Capital, LLCPassive investorSold down below 5%Since 28 February 2026
- Jain Global LLCPassive investorSold down below 5%Since 31 March 2026
- Novo Holdings A/SPassive investorSold down below 5%Since 7 October 2025
| Holder | Stake | Since | |
|---|---|---|---|
Fairmount Funds Management LLC Insider or founder | at least 20.0%0.0 pts (filed with 4 related holders) | 9 February 2026 | What they saidItem 4 of the Statement is hereby amended and supplemented as follows: Conversion of Series C Preferred Stock Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock, dated November 7,… Read the filing |
FMR LLC Passive investor | at least 15.0% (filed with 1 related holder) | 28 November 2025 | |
Avoro Capital Advisors LLC Passive investor | at least 6.3% (filed with 1 related holder) | 31 March 2026 | |
Venrock Healthcare Capital Partners III, L.P. Passive investor | at least 6.0% (filed with 6 related holders) | 9 February 2026 | |
BlackRock, Inc. Passive investor | 5.1% | 30 June 2026 | |
Point72 Asset Management, L.P. Passive investor | at least 2.0%−4.3 pts (filed with 2 related holders) | 31 March 2026 | |
Paragon Therapeutics, Inc. Passive investor | Sold down below 5% | 9 February 2026 | |
Paramora Holding LLC Passive investor | Sold down below 5% | 9 February 2026 | |
Ikarian Capital, LLC Passive investor | Sold down below 5% | 28 February 2026 | |
Jain Global LLC Passive investor | Sold down below 5% | 31 March 2026 | |
Novo Holdings A/S Passive investor | Sold down below 5% | 7 October 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $252,875 of shares on the open market. 3 sold $30,653.
- Jarrett JenniferDirector, President and CEO, DirectorBought
- Date
- 25 September 2026
- Shares
- 12,500
- Price
- $20.23
- Value
- $252,875
- Winslow GarrettGeneral CounselSold
- Date
- 6 July 2026
- Shares
- 245
- Price
- $29.98
- Value
- $7,345
- Schambye Hans T.Chief Executive Officer, DirectorSold
- Date
- 2 January 2026
- Shares
- 700
- Price
- $21.38
- Value
- $14,966
- Winslow GarrettGeneral CounselSold
- Date
- 2 January 2026
- Shares
- 255
- Price
- $21.38
- Value
- $5,452
- Firmani LoriChief Financial OfficerSold
- Date
- 2 January 2026
- Shares
- 135
- Price
- $21.41
- Value
- $2,890
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 25 September 2026 | Jarrett Jennifer Director, President and CEO, Director | Bought | 12,500 | $20.23 | $252,875 |
| 6 July 2026 | Winslow Garrett General Counsel | Sold | 245 | $29.98 | $7,345 |
| 2 January 2026 | Schambye Hans T. Chief Executive Officer, Director | Sold | 700 | $21.38 | $14,966 |
| 2 January 2026 | Winslow Garrett General Counsel | Sold | 255 | $21.38 | $5,452 |
| 2 January 2026 | Firmani Lori Chief Financial Officer | Sold | 135 | $21.41 | $2,890 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 19 Mar 2026, plus the 10-Q filed 10 Aug 2026 and 5 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.